The in vitro pharmacological properties of compound 23, that is, its potency and efficacy, reversible inhibition, receptor selectivity, lack of use‐dependent block, and relative peripheral stability, make it a potential drug candidate for local therapeutic intervention of peripheral neuropathies mediated by dysfunctional TRPM8 channels. This evidence concerns the gene TRPM8 and peripheral neuropathy.